Aequus Pharmaceuticals Inc. (CVE:AQS – Get Free Report) reached a new 52-week low during mid-day trading on Tuesday . The stock traded as low as C$0.01 and last traded at C$0.01, with a volume of 14000 shares changing hands. The stock had previously closed at C$0.01.
Aequus Pharmaceuticals Price Performance
The stock has a 50 day moving average of C$0.01 and a 200-day moving average of C$0.01. The company has a debt-to-equity ratio of 138.88, a quick ratio of 0.46 and a current ratio of 0.07. The company has a market cap of C$663,150.00, a PE ratio of -0.50 and a beta of -0.02.
About Aequus Pharmaceuticals
Aequus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease.
See Also
- Five stocks we like better than Aequus Pharmaceuticals
- What Investors Need to Know About Upcoming IPOs
- 3 Undervalued Stocks You Can Buy at a Discount Now
- Overbought Stocks Explained: Should You Trade Them?
- AMD Stock: Can the PC Refresh Cycle Spark a Rally?
- Why Invest in 5G? How to Invest in 5G Stocks
- Micron Stock Spikes 7%—3 Key Catalysts Behind the Move
Receive News & Ratings for Aequus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aequus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
